SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
---|---|---|---|---|---|---|---|---|---|
05-Mar-24 4:58 PM View: | Powell Andrew Kenneth William Director | Aclaris Therapeutics, Inc. (ACRS) | 04-Mar-24 | Purchase | 6,000 | $1.25 | $7,500.00 | 26% 22.86K to 28.86K | |
05-Mar-24 5:04 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Option Exercise | 12,500 | -- | -- | 7% 178.01K to 190.51K | |
05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Payment of Exercise | 427 | $1.24 | $529.48 | (2%) 24.41K to 23.98K | |
05-Mar-24 5:04 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Payment of Exercise | 3,531 | $1.24 | $4,378.44 | (2%) 190.51K to 186.98K | |
05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-24 | Option Exercise | 1,500 | -- | -- | 7% 22.91K to 24.41K | |
05-Mar-24 5:04 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Payment of Exercise | 17,752 | $1.24 | $22,012.50 | (9%) 195.76K to 178.01K | |
05-Mar-24 5:08 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Payment of Exercise | 3,223 | $1.24 | $3,996.52 | (< 1%) 1.28M to 1.28M | |
05-Mar-24 4:58 PM View: | Powell Andrew Kenneth William Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Private Purchase | 8,500 | $1.23 | $10,455.00 | 59% 14.36K to 22.86K | |
05-Mar-24 5:08 PM View: | Walker Neal Interim President and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Option Exercise | 9,466 | -- | -- | < 1% 1.27M to 1.28M | |
05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Option Exercise | 3,475 | -- | -- | 17% 20.43K to 23.9K | |
05-Mar-24 5:04 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Option Exercise | 60,925 | -- | -- | 45% 134.83K to 195.76K | |
05-Mar-24 5:02 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Mar-24 | Payment of Exercise | 990 | $1.24 | $1,227.60 | (4%) 23.9K to 22.91K | |
05-Feb-24 7:31 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Feb-24 | Payment of Exercise | 2,583 | $1.20 | $3,099.60 | (2%) 137.42K to 134.83K | |
05-Feb-24 7:29 PM View: | Loerop James Chief Business Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Feb-24 | Payment of Exercise | 6,421 | $1.20 | $7,705.20 | (16%) 40.44K to 34.02K | |
05-Feb-24 7:31 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Feb-24 | Option Exercise | 7,500 | -- | -- | 6% 129.92K to 137.42K | |
05-Feb-24 7:29 PM View: | Loerop James Chief Business Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Feb-24 | Option Exercise | 18,750 | -- | -- | 86% 21.69K to 40.44K | |
03-Jan-24 4:47 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Jan-24 | Payment of Exercise | 2,536 | $1.05 | $2,662.80 | (11%) 22.96K to 20.43K | |
03-Jan-24 4:44 PM View: | Manion Douglas J. Pres and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jan-24 | Payment of Exercise | 9,125 | $1.05 | $9,581.25 | (18%) 50.94K to 41.81K | |
03-Jan-24 4:47 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Jan-24 | Option Exercise | 7,500 | -- | -- | 49% 15.46K to 22.96K | |
03-Jan-24 4:44 PM View: | Manion Douglas J. Pres and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Jan-24 | Option Exercise | 27,000 | -- | -- | 113% 23.94K to 50.94K | |
25-Oct-23 4:28 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 23-Oct-23 | Sale (Planned) | 6,000 | $5.08 | $30,460.20 | (4%) 135.92K to 129.92K | |
07-Sep-23 4:16 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 06-Sep-23 | Private Purchase | 9,490 | $7.90 | $74,971.00 | 159% 5.97K to 15.46K | |
05-Sep-23 5:08 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Sep-23 | Payment of Exercise | 285 | $7.90 | $2,251.50 | (5%) 6.26K to 5.97K | |
05-Sep-23 5:08 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Sep-23 | Option Exercise | 1,000 | -- | -- | 19% 5.26K to 6.26K | |
28-Aug-23 4:39 PM View: | Loerop James Chief Business Officer | Aclaris Therapeutics, Inc. (ACRS) | 28-Aug-23 | Private Purchase | 14,705 | $6.80 | $99,958.70 | 211% 6.98K to 21.69K | |
22-Aug-23 4:31 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 21-Aug-23 | Sale (Planned) | 6,000 | $7.32 | $43,894.80 | (4%) 141.92K to 135.92K | |
03-Aug-23 4:24 PM View: | Manion Douglas J. Pres and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Aug-23 | Option Exercise | 15,575 | -- | -- | 122% 12.8K to 28.38K | |
03-Aug-23 4:24 PM View: | Manion Douglas J. Pres and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 01-Aug-23 | Payment of Exercise | 4,437 | $9.81 | $43,527.00 | (16%) 28.38K to 23.94K | |
05-Jul-23 4:23 PM View: | Cawkwell Gail Chief Medical Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Jul-23 | Payment of Exercise | 5,407 | $10.37 | $56,070.60 | (36%) 15.0K to 9.59K | |
05-Jul-23 4:23 PM View: | Cawkwell Gail Chief Medical Officer | Aclaris Therapeutics, Inc. (ACRS) | 01-Jul-23 | Option Exercise | 15,000 | -- | -- | 100% 0 to 15.0K | |
22-Jun-23 4:32 PM View: | Molineaux Christopher P. Director | Aclaris Therapeutics, Inc. (ACRS) | 20-Jun-23 | Option Exercise | 16,500 | $1.41 | $23,265.00 | 52% 32.0K to 48.5K | |
22-Jun-23 4:30 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 20-Jun-23 | Sale (Planned) | 6,000 | $10.28 | $61,662.60 | (4%) 147.92K to 141.92K | |
20-Jun-23 4:31 PM View: | Molineaux Christopher P. Director | Aclaris Therapeutics, Inc. (ACRS) | 15-Jun-23 | Option Exercise | 249 | $1.36 | $337.68 | < 1% 31.75K to 32.0K | |
05-Jun-23 4:50 PM View: | Powell Andrew Kenneth William Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 46% 9.86K to 14.36K | |
05-Jun-23 4:45 PM View: | Mehra Anand Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 13% 34.2K to 38.7K | |
05-Jun-23 5:08 PM View: | Milano Vincent Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 134% 3.36K to 7.86K | |
05-Jun-23 5:02 PM View: | Molineaux Christopher P. Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 17% 27.25K to 31.75K | |
05-Jun-23 4:57 PM View: | Reasons Bryan M. Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 23% 19.57K to 24.07K | |
05-Jun-23 5:12 PM View: | Humphries William D. Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 23% 19.57K to 24.07K | |
05-Jun-23 4:53 PM View: | Schiff Dr Drew Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 1% 434.45K to 438.96K | |
05-Jun-23 5:04 PM View: | Gowen Maxine Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Jun-23 | Option Exercise | 4,507 | -- | -- | 58% 7.79K to 12.3K | |
17-Mar-23 5:03 PM View: | Manion Douglas J. Pres and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 17-Mar-23 | Private Purchase | 6,300 | $7.86 | $49,532.50 | 97% 6.5K to 12.8K | |
09-Mar-23 5:56 PM View: | Manion Douglas J. Pres and CEO Director | Aclaris Therapeutics, Inc. (ACRS) | 09-Mar-23 | Private Purchase | 6,500 | $7.74 | $50,277.50 | 100% 0 to 6.5K | |
03-Mar-23 10:00 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 03-Mar-23 | Option Sale | 16,037 | $12.63 | $202,615.00 | (10%) 163.95K to 147.92K | |
03-Mar-23 10:00 PM View: | Walker Neal Director | Aclaris Therapeutics, Inc. (ACRS) | 03-Mar-23 | Option Sale | 30,240 | $12.63 | $382,070.00 | (2%) 1.3M to 1.27M | |
03-Mar-23 10:00 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 03-Mar-23 | Option Sale | 894 | $12.63 | $11,289.50 | (15%) 6.15K to 5.26K | |
03-Mar-23 10:00 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-23 | Option Exercise | 1,500 | -- | -- | 27% 5.65K to 7.15K | |
03-Mar-23 10:00 PM View: | Walker Neal Director | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-23 | Option Sale | 29,000 | $12.37 | $358,588.00 | (2%) 1.33M to 1.3M | |
03-Mar-23 10:00 PM View: | Balthaser Kevin Chief Financial Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-23 | Option Sale | 1,000 | $12.29 | $12,289.00 | (14%) 7.15K to 6.15K | |
03-Mar-23 10:00 PM View: | Monahan Joseph Chief Scientific Officer | Aclaris Therapeutics, Inc. (ACRS) | 02-Mar-23 | Option Sale | 14,800 | $12.37 | $183,024.00 | (8%) 178.75K to 163.95K |